ClinicalTrials.gg
RecruitingNCT07189338APNEICUpdated Nov 9, 2026

Apneic Oxygenation With High-flow Nasal Oxygenation After Preoxygenation With Noninvasive Ventilation Before Intubation in Hypoxemic Patients in Intensive Care Unit.

An interventional study of Apneic oxygenation and Usual Care in Hypoxemic Acute Respiratory Failure, sponsored by University Hospital, Tours. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Tours · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 9, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 127 studies in Respiratory Insufficiency with a site in France — 20 open to participants now, 21 under way, 2 of them phase 3. Respiratory Insufficiency · France.

Planned enrollment
11th of 78
500 · median 82
Started
2026
with 6 others
No phase
64 of 127
13 open now
Primary completion
2029-03
later than 19 of 20 live
Registered
122nd of 127
by date

Among the 127 studies in Respiratory Insufficiency with a site in France, this one is the 11th largest by planned enrollment of the 78 interventional ones that give a count, is one of 7 that started in 2026, is one of 64 with no phase, reaches primary completion later than 19 of the 20 other live ones, and was the 122nd registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

20 of the 127 studies in Respiratory Insufficiency with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Respiratory Insufficiency with a site in France, or all of them as a file.
02

Study summary

The aim of this clinical study is to assess whether apneic oxygenation with High-Flow Nasal Oxygen (HFNO) would decrease the incidence of severe hypoxemia compared to no apneic oxygenation during the intubation procedure (from the start of laryngoscopy to 5 minutes after successful intubation) in patients with hypoxemic acute respiratory failure.

The sponsor expects that apneic oxygenation (between the laryngoscopy and the success of intubation) with HFNO compared to no apneic oxygenation could decrease the risk of severe hypoxemia after intubation in hypoxemic critical ill patients.

Participants will be enrolled according to eligibility criteria and randomized into one of the following groups:

Experimental group : Apneic oxygenation will be used with HFNO between the laryngoscopy and the successful intubation (study intervention).

non-invasive ventilation (NIV) alone will be used for the preoxygenation and hypoventilation phase until the laryngoscopy. The nasal cannulas of HFNO will be placed on hold beneath the patient's chin (with HFNO on and set with a flow at 60-70L.min-1, FiO2 1.0) pending laryngoscopy began.

At the time of laryngoscopy: after removing the facemask of NIV, the nasal cannulas for HFNO will be placed in the patient's nares then the laryngoscopy will be performed.

Control group: The control group will receive usual care, i.e., no oxygen during the apneic phase (between the laryngoscopy and the success of the intubation procedure) During the preoxygenation and hypoventilation phase until laryngoscopy, NIV alone will be used as in the experimental group.

Read the detailed description

Endotracheal intubation is often performed in intensive care unit (ICU). Severe complications (such as severe hypoxemia, hypotension, cardiac arrest) occur up to 50%. Severe hypoxemia is more frequent in patients with hypoxemia prior to intubation or during difficult intubation and could increase the risk of cardiac arrest.

The procedure of intubation includes, in order 1) a preoxygenation phase ending with iv administration of anesthetic drugs 2) a hypoventilation phase 3) an apneic phase beginning with laryngoscopy and ending with successful intubation 4) mechanical ventilation. Optimization of this procedure is essential.

Non-invasive ventilation (NIV) is recommended for preoxygenation in hypoxemic patients and this technique can maintain ventilation during the hypoventilation phase.

Apneic oxygenation is defined as the administration of oxygen during the apneic phase. The objective is to increase the duration of apnea without desaturation. In physiological studies and in the operating room, when apneic oxygen is used with standard oxygen (up to 15L/min) or high-flow nasal oxygenation (HFNO) (up to 70L/min and FiO2 at 1.0), the apnea length without desaturation can reach several minutes.

Several meta-analyses (with high heterogeneity between studies) found that apneic oxygenation (including standard oxygen or HFNO) in emergency intubation could decrease the risk of hypoxemia. In most studies that investigated the effect of HFNO as apneic oxygenation, HFNO was also used as a preoxygenation method. Thus, the different methods of preoxygenation could affect the real effect of apneic oxygenation.

Only one single-center study evaluated apneic oxygenation with HFNO after preoxygenation by NIV. In this study the lowest SpO2 during intubation procedure was significantly higher in the apneic oxygenation group. However, in this study the mask used for NIV was applied over the nasal cannulas of HFNO, which may have resulted in less efficient preoxygenation due to leakage.

Intubation rate for HFNO failure during acute respiratory failure is about 40% in ICU patients. The question of continuing HFNO or not during the apnea phase remains open. The experts suggest continuing HFNO during intubation (conditional recommendation, moderate certainty).

We hypothesized that apneic oxygenation (between the laryngoscopy and the success of intubation) with HFNO compared to no apneic oxygenation could decrease the risk of severe hypoxemia after intubation in hypoxemic critical ill patients.

In both groups, NIV will be used during the preoxygenation and hypoventilation phases.

Procedure of intubation will be standardized according to guidelines

  • Preoxygenation will be performed using NIV through a facemask in both group

    1. Experimental group: The nasal cannulas of HFNO will be placed on hold beneath the patient's chin (with HFNO on and set with a flow at 60-70L.min-1, FiO2 1.0) pending laryngoscopy began.
    2. Control group: no HFNO
  • Rapide sequence induction (etomidate or ketamine + succinylcholine or rocuronium)
  • Hypoventilation phase will be continue in both groupe for 1min using NIV through a facemask
  • At the time of laryngoscopy :

    1. Experimental group: after removing the facemask of NIV, the nasal cannulas for HFNO will be placed in the patient's nares then the laryngoscopy will be performed.
    2. Control group: After removing the facemask, laryngoscopy will be performed without oxygen.
  • recommandation of using a videolaryngoscope with a bougie or stylet
  • Use of capnography to confirm the success of procedure
  • initiate or increase vasopressors if needed
  • Initiation of long-term sedation
  • Initiation protective ventilation
03

Conditions studied

  • Hypoxemic Acute Respiratory Failure

Keywords

  • IUC
  • Hypoxemic acute respiratory failure
  • HFNO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient admitted in the ICU
  • Indication of orotracheal intubation for Hypoxemic acute respiratory failure defined by:

    • One sign of acute respiratory distress (respiratory rate >25/min, dyspnea or the use of accessory respiratory muscle)
    • AND a PaO2/FiO2 ≤ 200 mmHg (measured or calculated FiO2) within 6 hours before the decision of intubation. For the calculation of FiO2, the FiO2 will be estimated by: FiO2 = 0.21 + 0.03 x (flow of oxygen) (Coudroy, Thorax 2020)
  • from the patient or relatives. An emergency procedure will be possible when necessary.

Exclusion criteria

Exclusion Criteria:

  • \< 18 years old

    • Need for emergent intubation (i.e. cardiac arrest)
    • to non-invasive ventilation for preoxygenation
    • Known allergy or contraindication to one of the induction drugs
    • SpO2 device specific for the study not available
    • Patients without any healthcare insurance scheme or not benefiting from it through a third party,
    • Persons under law protection, namely minors, pregnant or breastfeeding women, persons deprived of their liberty by a judicial or administrative decision
    • Previous participation in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Apneic oxygenation will be used with HFNO between the laryngoscopy and the successful intubation (study intervention). NIV alone will be used for the preoxygenation and hypoventilation phase until the laryngoscopy. Apneic oxygenation will be used with HFNO at the time of laryngoscopy after removing the facemask of NIV (with HFNO on and set with a flow at 60-70L.min-1, FiO2 1.0)

    Procedure: Apneic oxygenation

  • Other
    Control group

    The control group will receive usual care, i.e., no oxygen during the apneic phase (between the laryngoscopy and the success of the intubation procedure) During the preoxygenation and hypoventilation phase until laryngoscopy, NIV alone will be used as in the experimental group.

    Procedure: Usual Care

Interventions

  • ProcedureApneic oxygenation

    * Preoxygenation will be performed using NIV for 3-5 min With nasal cannulas placed in standby beneath the patient's chin (with HFNO on and set with a flow at 60-70L.min-1, FiO2 1.0) * Rapide sequence induction * Hypoventilation phase will be continue for 1 min using NIV * At the time of laryngoscopy : After removing the facemask, the nasal cannulas of HFNO will be placed in the patient's nares then the laryngoscopy will be performed. \* Use of capnography to confirm the success of procedure

  • ProcedureUsual Care

    * Preoxygenation will be performed using NIV for 3-5 min without HFNO * Rapide sequence induction * Hypoventilation phase will be continue using NIV for 1min * At the time of laryngoscopy : After removing the facemask, laryngoscopy will be performed without oxygen. \* Use of capnography to confirm the success of procedure

06

What researchers measure

Primary outcomes

  1. Incidence of severe hypoxemia

    The incidence of severe hypoxemia defined as the occurrence of at least one episode of oxygen saturation measured by pulse oximetry (SpO2) \< 80%

    Time frame: from the start of laryngoscopy to 5 minutes after successful intubation

Secondary outcomes

  1. Incidence of prolonged severe hypoxemia

    The incidence of prolonged severe hypoxemia defined by an SpO2 \< 80% for more than 24 seconds

    Time frame: from the start of laryngoscopy to 5 minutes after successful intubation

  2. The highest and lowest SpO2 values during the procedure

    The highest and lowest SpO2 values during the procedure

    Time frame: from the start of laryngoscopy to 5 minutes after successful intubation

  3. The occurrence of each immediate severe complications

    The occurrence of each immediate severe complications including cardiovascular instability (systolic arterial blood pressure \<65 mmHg at least once, new or increase need of vasopressors or fluid bolus \>15 mL/kg), cardiac arrest, new onset cardiac arrhythmia (atrial fibrillation, ventricular tachycardia, bradycardia \<30beats per minute).

    Time frame: from the start of laryngoscopy to 5 minutes after successful intubation

  4. The occurrence of each other adverse events

    The occurrence of each other adverse events: difficult intubation (defined as a procedure requiring more than 2 laryngoscopy attempts before success), operator-reported aspiration between induction and intubation, dental injury, esophageal intubation, pneumothorax visualized on the follow-up chest X-ray as part of the patient's routine care.

    Time frame: from the start of laryngoscopy to 5 minutes after successful intubation; At Day 28

  5. Duration of laryngoscopy

    The duration of laryngoscopy will be compared in both group

    Time frame: From the 1st attempt to the successful intubation

  6. Number of laryngoscopies

    The number of laryngoscopies will be compared in both group

    Time frame: from the 1st attempt to the successful intubation

  7. Day-28 mortality

    Time frame: at Day 28

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.

Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 36 months is above that.

Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Oct 2025 → Mar 2026, primary completion Oct 2028 → Mar 2029 and completion Nov 2028 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2025
First posted
Sep 23, 2025
StartActual
Mar 20, 2026was Oct 2025
Primary completionEst.
Mar 2029was Oct 2028
CompletionEst.
Apr 2029was Nov 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
CHRU de Tours is now Recruiting
Nov 9, 2026
Start date
Oct 30, 2025→Mar 20, 2026 (actual)
Nov 9, 2026
Primary completion
Oct 30, 2028→Mar 2029
Nov 9, 2026
Study completion
Nov 30, 2028→Apr 2029
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    CHRU de Tours is now Recruiting
    Start date Oct 30, 2025→Mar 20, 2026 (now actual)
    Primary completion Oct 30, 2028→Mar 2029
    Study completion Nov 30, 2028→Apr 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07189338
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Mar 20, 2026
Primary completion
Mar 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Mai-Anh Nay, MD
Contact
mainah.nay@chu-orleans.fr
+33 2 38 57 52 53

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion